CL2011002639A1 - Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis. - Google Patents

Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.

Info

Publication number
CL2011002639A1
CL2011002639A1 CL2011002639A CL2011002639A CL2011002639A1 CL 2011002639 A1 CL2011002639 A1 CL 2011002639A1 CL 2011002639 A CL2011002639 A CL 2011002639A CL 2011002639 A CL2011002639 A CL 2011002639A CL 2011002639 A1 CL2011002639 A1 CL 2011002639A1
Authority
CL
Chile
Prior art keywords
bovis
bacterial strain
immunogenic composition
medicine
infections caused
Prior art date
Application number
CL2011002639A
Other languages
English (en)
Inventor
Michael Knittel Jeffrey Beck
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of CL2011002639A1 publication Critical patent/CL2011002639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Cepa bacteriana de M. bovis atenuada avirulenta; composición inmunogénica que la comprende; método para atenuar M. bovis; y método de tratamiento o profilaxis de infecciones producidas por M. bovis.
CL2011002639A 2009-04-24 2011-10-21 Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis. CL2011002639A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17254309P 2009-04-24 2009-04-24

Publications (1)

Publication Number Publication Date
CL2011002639A1 true CL2011002639A1 (es) 2012-07-20

Family

ID=42331013

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002639A CL2011002639A1 (es) 2009-04-24 2011-10-21 Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.

Country Status (20)

Country Link
US (1) US9339533B2 (es)
EP (1) EP2421556B1 (es)
JP (1) JP5793808B2 (es)
KR (1) KR101880888B1 (es)
CN (1) CN102458461B (es)
AR (1) AR076413A1 (es)
AU (1) AU2010238689B2 (es)
BR (1) BRPI1013836B1 (es)
CA (1) CA2758733C (es)
CL (1) CL2011002639A1 (es)
CO (1) CO6460761A2 (es)
DK (1) DK2421556T3 (es)
ES (1) ES2630209T3 (es)
HU (1) HUE033618T2 (es)
MX (1) MX342443B (es)
NZ (1) NZ595914A (es)
PL (1) PL2421556T3 (es)
SG (2) SG175323A1 (es)
UY (1) UY32570A (es)
WO (1) WO2010124154A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121721A4 (en) * 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
WO2010051210A1 (en) 2008-10-31 2010-05-06 Boehringer Ingelheim Vetmedica, Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
US8440203B2 (en) * 2009-11-06 2013-05-14 Intervet Inc. Methods of immunizing pregnant heifers at three months of gestation
CN102294026A (zh) * 2010-11-17 2011-12-28 赤峰博恩药业有限公司 奶牛链球菌乳房炎灭活疫苗及其制备方法
US9175049B2 (en) 2012-10-24 2015-11-03 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
ES2771598T3 (es) 2013-12-18 2020-07-06 Asahi Chemical Ind Procedimiento para detectar bacterias del género Streptococcus en la leche
CN103800901B (zh) * 2014-01-27 2015-12-09 内蒙古华希生物科技有限公司 链球菌以及将其灭活得到的奶牛乳房炎疫苗
SI3334454T1 (sl) * 2015-08-14 2023-02-28 Zoetis Services Llc Sestave mycoplasma bovis
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN107815439A (zh) * 2016-09-14 2018-03-20 华威特（江苏）生物制药有限公司 牛传染性鼻气管炎病毒jsm株及其应用
CN107759674B (zh) * 2017-09-26 2021-12-28 中国农业科学院哈尔滨兽医研究所 一种牛支原体免疫相关性蛋白、含有该蛋白的检测试剂盒及其在牛支原体抗体检测中的用途
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN109847060A (zh) * 2019-04-19 2019-06-07 黑龙江八一农垦大学 牛多杀性巴氏杆菌病、溶血性曼氏杆菌病二联灭活疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111733094B (zh) * 2020-05-29 2022-09-09 内蒙古民族大学 一种牛源蜡样芽孢杆菌及其应用
AR124849A1 (es) 2021-02-11 2023-05-10 Intervet Int Bv Vacuna para mycoplasma bovis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002670A1 (en) 1997-07-10 1999-01-21 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1229929A2 (en) * 1999-11-08 2002-08-14 Biomune VACCINES FOR i MYCOPLASMA BOVIS /i AND METHODS OF USE
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
CN1612749A (zh) 2001-07-02 2005-05-04 辉瑞产品公司 用于减弱牲畜体内牛支原体肺炎的猪肺炎支原体疫苗和方法
MXPA04001872A (es) 2001-08-28 2004-06-15 Pfizer Prod Inc Modelo de exposicion a micoplasma bovis, procedimiento para administrar m. bovis y procedimientos para inducir lesiones pulmonares neumonicas.
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
EP2121721A4 (en) 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
CN100419073C (zh) * 2006-09-28 2008-09-17 中国兽医药品监察所 猪喘气病活疫苗及其生产方法
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
WO2010002537A1 (en) 2008-07-03 2010-01-07 Iowa State University Research Foundation, Inc. Cattle vaccines
WO2010051210A1 (en) 2008-10-31 2010-05-06 Boehringer Ingelheim Vetmedica, Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
EP2421556B1 (en) 2017-04-05
UY32570A (es) 2010-11-30
JP2012524548A (ja) 2012-10-18
CN102458461B (zh) 2017-03-08
HUE033618T2 (en) 2017-12-28
CA2758733C (en) 2019-12-24
AR076413A1 (es) 2011-06-08
WO2010124154A1 (en) 2010-10-28
MX342443B (es) 2016-09-29
CN102458461A (zh) 2012-05-16
NZ595914A (en) 2014-09-26
DK2421556T3 (en) 2017-07-10
BRPI1013836B1 (pt) 2020-04-14
US20100272759A1 (en) 2010-10-28
SG175323A1 (en) 2011-11-28
CO6460761A2 (es) 2012-06-15
AU2010238689B2 (en) 2017-01-19
AU2010238689A1 (en) 2011-11-03
KR20120109992A (ko) 2012-10-09
JP5793808B2 (ja) 2015-10-14
PL2421556T3 (pl) 2017-09-29
KR101880888B1 (ko) 2018-07-23
EP2421556A1 (en) 2012-02-29
MX2011010976A (es) 2011-11-18
ES2630209T3 (es) 2017-08-18
SG10201401784WA (en) 2014-08-28
US9339533B2 (en) 2016-05-17
CA2758733A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CR20150218A (es) Métodos y composiciones para el tratamiento y control de enfermedades en las plantas
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112014030025A2 (pt) composições de polissacarídeo e métodos de uso
CL2008002675A1 (es) Bacteria de mycoplasma gallisepticum atenuada; composicion de vacuna que la comprende; método de vacunación; y método de identificación de clones de mycoplasma gallisepticum atenuados.
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
CL2011001284A1 (es) Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab.
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112012021383A2 (pt) tratamento ou prevencao de infeccao
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
BR112012033121A2 (pt) métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
BR112022005345A2 (pt) Composições imunogênicas
BR112016012393A8 (pt) vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado
GB2515222A (en) Use of flagellin as a vaccine
MX368601B (es) Composicion inmunogenica contra la aeromonas hydrophila.
PL404229A1 (pl) Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie